Treatment of multiple sclerosis: current concepts and future perspectives

被引：40

作者：

Buck, Dorothea ^{[1
]}

Hemmer, Bernhard ^{[1
]}

机构：

[1] Tech Univ Munich, Dept Neurol, Klinikum Rechts Isar, D-81675 Munich, Germany

来源：

JOURNAL OF NEUROLOGY | 2011年 / 258卷 / 10期

关键词：

Multiple sclerosis; Treatment; Immunotherapy; Clinical trials; PLACEBO-CONTROLLED TRIAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; FINGOLIMOD FTY720 TREATMENT; INTERFERON-BETA THERAPY; CENTRAL-NERVOUS-SYSTEM; JC VIRUS-DNA; DOUBLE-BLIND; NEUTRALIZING ANTIBODIES; GLATIRAMER ACETATE; INTRAMUSCULAR INTERFERON;

D O I：

10.1007/s00415-011-6101-2

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Currently, several disease-modifying therapies for the treatment of multiple sclerosis are established and more are likely to be introduced. These treatment options differ with respect to their application profile, mechanism of action, efficacy, safety, and tolerance. Here, we review current concepts of MS therapies, report recent results of clinical trials, and discuss emerging treatment options.

引用

页码：1747 / 1762

页数：16

共 116 条

[1] Benefit-Risk Assessment of Leflunomide An Appraisal of Leflunomide in Rheumatoid Arthritis 10 Years After Licensing [J].

Alcorn, Nicola ;

Saunders, Sarah ;

Madhok, Rajan .

DRUG SAFETY, 2009, 32 (12) :1123-1134

[2] Daclizumab in treatment of multiple sclerosis patients [J].

Ali, E. N. ;

Healy, B. C. ;

Stazzone, L. A. ;

Brown, B. A. ;

Weiner, H. L. ;

Khoury, S. J. .

MULTIPLE SCLEROSIS JOURNAL, 2009, 15 (02) :272-274

[3] Temporal trends in the incidence of multiple sclerosis [J].

Alonso, Alvaro ;

Hernan, Miguel A. .

NEUROLOGY, 2008, 71 (02) :129-135

[4] Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications [J].

Arnon, R ;

Aharoni, R .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 :14593-14598

[5] PEGylated Interferon Beta-1a: Meeting an Unmet Medical Need in the Treatment of Relapsing Multiple Sclerosis [J].

Baker, Darren P. ;

Pepinsky, Robert Blake ;

Brickelmaier, Margot ;

Gronke, Robert S. ;

Hu, Xiao ;

Olivier, Kenneth ;

Lerner, Michaela ;

Miller, Larisa ;

Crossman, Mary ;

Nestorov, Ivan ;

Subramanyam, Meena ;

Hitchman, Stacy ;

Glick, Gabrielle ;

Richman, Sandra ;

Liu, Shifang ;

Zhu, Ying ;

Panzara, Michael A. ;

Davar, Gudarz .

JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2010, 30 (10) :777-785

[6] Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial [J].

Bar-Or, Amit ;

Calabresi, Peter A. J. ;

Arnlod, Douglas ;

Markowitz, Clyde ;

Shafer, Stuart ;

Kasper, Lloyd H. ;

Waubant, Ernmanuelle ;

Gazda, Suzanne ;

Fox, Robert J. ;

Panzara, Michael ;

Sarkar, Neena ;

Agarwal, Sunil ;

Smith, Craig H. .

ANNALS OF NEUROLOGY, 2008, 63 (03) :395-400

[7] LEFLUNOMIDE (HWA-486), A NOVEL IMMUNOMODULATING COMPOUND FOR THE TREATMENT OF AUTOIMMUNE DISORDERS AND REACTIONS LEADING TO TRANSPLANTATION REJECTION [J].

BARTLETT, RR ;

DIMITRIJEVIC, M ;

MATTAR, T ;

ZIELINSKI, T ;

GERMANN, T ;

RUDE, E ;

THOENES, GH ;

KUCHLE, CCA ;

SCHORLEMMER, HU ;

BREMER, E ;

FINNEGAN, A ;

SCHLEYERBACH, R .

AGENTS AND ACTIONS, 1991, 32 (1-2) :10-21

[8] Interferon β neutralizing antibodies in multiple sclerosis:: neutralizing activity and cross-reactivity with three different preparations [J].

Bertolotto, A ;

Malucchi, S ;

Milano, E ;

Castello, A ;

Capobianco, M ;

Mutani, R .

IMMUNOPHARMACOLOGY, 2000, 48 (02) :95-100

[9] CLADRIBINE (2-CHLORODEOXYADENOSINE) [J].

BEUTLER, E .

LANCET, 1992, 340 (8825) :952-956

[10]

BEUTLER E, 1994, SEMIN HEMATOL, V31, P40

← 1 2 3 4 5 6 7 8 9 10 →